Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Favorite
Share
More Options
23

Open in WPS to view all 23 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
